Sigma-1 Receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases – Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases

New York, NY — January 23, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer’s. The report demonstrates for the first time, evidenced by human brain…